Publications by authors named "Francesco De Cesaris"

Claim this Profile
P
Placebo Effect of Verbal Instructions Coupled with Pharmacological Treatment: Results from a Randomized Controlled Trial in Migraine Patients.
Sara Romanazzo, Francesca Monti, Sara Ceccatelli, Francesco De Cesaris, Alberto Chiarugi

Psychother Psychosom· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corticosteroid-dependent increased expression of CGRP and its receptor subunits within the rodent trigeminal ganglion does not prompt cephalic allodynia.
Alessandra Pistolesi, Simone Tuniz, Andrea Lapucci, Alice Molli, Francesco De Cesaris

Cephalalgia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biodistribution of atogepant and rimegepant in mouse peripheral and central structures of relevance to migraine pathogenesis.
Alessandra Pistolesi, Francesco De Cesaris, Daniela Buonvicino, Alberto Chiarugi

Cephalalgia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical outcome of patients starting monoclonal antibodies anti-CGRP with concomitant migraine preventive treatments.
Luisa Fofi, Claudia Altamura, Marilena Marcosano, Nicoletta Brunelli, Luigi Francesco Iannone, Francesco De Cesaris

Cephalalgia· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A nomogram for the prediction of response to anti-CGRP mAbs: the CGRP score.
Marina Romozzi, Ammar Lokhandwala, Catello Vollono, David García-Azorín, Giulia Vigani, Francesco De Cesaris

J Headache Pain· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex differences in the clinical features of 2,841 patients with migraine: a , multicenter, cross-sectional study.
Marina Romozzi, Luigi Francesco Iannone, Marcello Silvestro, Giulia Paparella, Stefania Scannicchio, Francesco De Cesaris

Front Neurol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction of opioid withdrawal symptoms and opioid-induced hyperalgesia by subcutaneous sumatriptan reveals central neuromodulation.
Alessandra Pistolesi, Francesco De Cesaris, Daniela Buonvicino, Alberto Chiarugi

J Pain· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real world effectiveness of anti-CGRP monoclonal antibodies over three consecutive one-year treatment cycles: An intention-to-treat analysis.
Gloria Vaghi, Michele Corrado, Maria Magdalena Pocora, Federico Bighiani, Francescantonio Cammarota, Francesco De Cesaris

Cephalalgia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CGRP monoclonal antibodies counteract establishment of food aversive memories and chemotherapy-induced anorexia and weight loss.
Alessandra Pistolesi, Simone Tuniz, Cristina Luceri, Alice Molli, Matteo Urru, Francesco De Cesaris

Pharmacol Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-domain destructuring in the early phases of psychosis: a multicentric phenomenological and psychometric case-control study.
Ottone Baccaredda Boy, Giuseppe Pierpaolo Merola, Andrea Patti, Bernardo Bozza, Dario Flaccomio, Francesco De Cesaris

Front Behav Neurosci· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients' Global Impression of Change (PGIC) Score Compared to Monthly Migraine Days to Evaluate Treatment Persistence With Anti-CGRP Monoclonal Antibodies.
Marina Romozzi, Catello Vollono, Paolo Calabresi, Francesco De Cesaris, Luigi Francesco Iannone

Ann Clin Transl Neurol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of triptans use on anti-CGRP mAbs response: a prospective, cohort study.
Catello Vollono, Marina Romozzi, Antonio Munafò, Giulia Vigani, Francesco De Cesaris

J Neurol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The anti-CGRP mAb Fremanezumab reverts the anti-inflammatory effects of CGRP in vitro but does not alter disease evolution in a mouse model of progressive multiple sclerosis.
Alessandra Pistolesi, Alice Molli, Francesco De Cesaris, Alberto Chiarugi, Daniela Buonvicino

Eur J Pharmacol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study).
Fabrizio Vernieri, Luigi Francesco Iannone, Flavia Lo Castro, Gabriele Sebastianelli, Federico De Santis, Francesco De Cesaris

Cephalalgia· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological differences and switching among anti-CGRP monoclonal antibodies: A narrative review.
Marina Romozzi, Antonio Munafò, Andrea Burgalassi, Francesco De Cesaris, Giulia Vigani

Headache· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: A prospective cohort study.
Andrea Burgalassi, Marina Romozzi, Giulia Vigani, Roberto De Icco, Bianca Raffaelli, Francesco De Cesaris

Cephalalgia· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mental Pain Questionnaire: Clinimetric Properties of a Potential Global Person-Centred Outcome Measure.
Fiammetta Cosci, Danilo Carrozzino, Chiara Patierno, Sara Romanazzo, Carmen Berrocal, Francesco De Cesaris

Clin Psychol Psychother· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Treatment with the Calcitonin Gene-Related Peptide Receptor Antagonist Erenumab in CADASIL: Two Case Reports.
Maria Albanese, Francesca Pescini, Chiara Di Bonaventura, Luigi Francesco Iannone, Silvia Bianchi, Francesco De Cesaris

J Clin Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of anti-CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy.
Giulia Hyeraci, Olga Paoletti, Luigi Francesco Iannone, Rosa Gini, Francesco De Cesaris

Headache· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study.
Valeria Caponnetto, Antonio Russo, Marcello Silvestro, Alessandro Tessitore, Roberto De Icco, Francesco De Cesaris

CNS Drugs· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the Italian version of the Cluster Headache Impact Questionnaire (CHIQ).
Agnese Onofri, Luigi Francesco Iannone, Antonio Granato, Gabriele Garascia, Luca Bartole, Francesco De Cesaris

Neurol Sci· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.
Luigi Francesco Iannone, Andrea Burgalassi, Giulia Vigani, Giorgio Tabasso, Francesco De Cesaris

Cephalalgia· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine.
Luigi Francesco Iannone, Davide Fattori, Martina Marangoni, Silvia Benemei, Alberto Chiarugi, Francesco De Cesaris

CNS Drugs· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilization patterns, cardiovascular risk, and concomitant serotoninergic medications among triptan users between 2008 and 2018: A gender analysis in one Italian region, Tuscany.
Giulia Hyeraci, Rosa Gini, Julien Bezin, Luigi Francesco Iannone, Silvia Benemei, Francesco De Cesaris

Headache· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine.
Luigi Francesco Iannone, Francesco De Cesaris, Anita Ferrari, Silvia Benemei, Davide Fattori

Cephalalgia· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis